Source-grounded facts extracted from CVRx, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Jared Oasheim resigned as Chief Financial Officer at CVRx, Inc..
“On June 7, 2026, Jared Oasheim, the Chief Financial Officer (“CFO”) of CVRx, Inc. (the “Company”), gave notice of his intention to resign from the Company to pursue other professional opportunities.”
CVRx, Inc. shareholders approved Ratification of Grant Thornton LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-01 meeting.
“The stockholders ratified the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026, by the votes set forth in the table below.”
CVRx, Inc. shareholders approved Election of three Class II directors at the 2026-06-01 meeting.
“The three nominees for Class II director were elected to serve until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified, by the votes set forth in the table below.”
CVRx, Inc. reported first quarter ended March 31, 2026 results: revenue $14.8 million, net income $13.1 million, or $0.50 per share, EPS $0.50 per share. Guidance reaffirmed.
“cardiovascular diseases, today announced its financial and operating results for the first quarter of 2026. Recent Highlights · Total revenue for the first quarter of 2026 was $14.8 million, an increase of approximately 20% over the prior year quarter · U.S. revenue for the first quarter of 2026 was $13.7 million, an increase of 22% over the prior year quarter ·”
CVRx, Inc. reported first quarter ended March 31, 2026 results: revenue $14.7 million to $14.8 million.
“EXHIBIT 99.1 Exhibit 99.1 CVRx Reports Preliminary First Quarter 2026 Financial Results · Delivered strong topline performance with first quarter revenue expected to be $14.7 million to $14.8 million, approximately 20% growth compared to first quarter of 2025 · Early data in 2026 shows an increase in the 30-day approval rate for Medicare Advantage prior”
CVRx, Inc. amended Amendment with Innovatus Life Sciences Fund I, LP valued at $50 million (effective 2026-01-09).
“On January 9, 2026 (the “Closing Date”), CVRx, Inc. (the “Company”) entered into an amendment (the “Amendment”) to its existing Loan and Security Agreement dated October 31, 2022, as previously amended on March 13, 2023 (as amended, the “Loan Agreement”), among the Company, Innovatus Life Sciences Fund I, LP, as the collateral agent and a lender, and the other lenders from time to time party thereto.”
CVRx, Inc. entered into Open Market Sale Agreement with Jefferies LLC valued at up to $50.0 million (effective 2026-01-12).
“On January 12, 2026, CVRx, Inc. (the “Company”) entered into an Open Market Sale Agreement SM (the “Sale Agreement”) with Jefferies LLC (the “Agent”).”
CVRx, Inc. amended credit facility of $50 million with Innovatus Life Sciences Fund I, LP at floating rate per annum equal to the sum of (i) the greater of (A) the prime rat maturing May 9, 2031.
“Pursuant to the Amendment, (a) the terms loans available to the Company are increased by $50 million, to an aggregate principal amount of up to $100 million”
CVRx, Inc. incurred term loan of $10 million with Innovatus Life Sciences Fund I, LP at prime rate plus 2.65% maturing May 9, 2031.
“revenue exceeds $100 million. The term loans continue to be secured by substantially all of the Company’s assets. Also on the Closing Date, the Company borrowed an additional $10 million under the Loan Agreement, bringing the total outstanding principal amount of term loans to $60 million. The Company has the option to draw (i) $15 million between June 1, 2027”
Ali Behbahani resigned as Director at CVRx, Inc..
“On August 27, 2024, Ali Behbahani gave notice of his intention to resign from the Board effective at the close of business on September 2, 2024.”
Mitch Hill was appointed as Director at CVRx, Inc..
“On August 30, 2024, the Board of Directors (the “Board”) of CVRx, Inc. (the “Company”) appointed Kevin Ballinger and Mitch Hill as directors, effective September 3, 2024.”
Kevin Ballinger was appointed as Director at CVRx, Inc..
“On August 30, 2024, the Board of Directors (the “Board”) of CVRx, Inc. (the “Company”) appointed Kevin Ballinger and Mitch Hill as directors, effective September 3, 2024.”
CVRx, Inc. reported the first quarter of 2024 results: revenue $10.8 million, net income $22.2 million, or $1.04 per share, EPS $1.04 per share. Guidance reaffirmed.
“cardiovascular diseases, today announced its financial and operating results for the first quarter of 2024. Recent Highlights · Total revenue for the first quarter 2024 was $ 10.8 million, an increase of 35 % over the prior year quarter · U.S. Heart Failure (HF) revenue for the first quarter of 2024 was $ 9.7 million, an increase of 43 % over the prior year”
Nadim Yared retired as Chief Executive Officer at CVRx, Inc..
“Mr. Yared will retire from the Board at the time of his retirement as CEO and will consult with the Company to ensure a seamless transition.”
Kevin Hykes was appointed as President and Chief Executive Officer at CVRx, Inc..
“On January 31, 2024, CVRx, Inc. (the “Company”) announced that its Board of Directors (the “Board”) appointed Kevin Hykes as President and Chief Executive Officer (“CEO”), effective February 12, 2024.”
CVRx, Inc. updated its the quarter and year ended December 31, 2023 guidance (reaffirmed).
“On January 25, 2024, CVRx, Inc. issued a press release announcing its financial results for the quarter and year ended December 31, 2023.”
CVRx, Inc. reported the fiscal year ended December 31, 2023 results: revenue approximately $39.2 million to $39.3 million. Guidance initiated.
“Total revenue for full year 2023 is expected to be in the range of approximately $39.2 million to $39.3 million”
CVRx, Inc. reported the fourth quarter ended December 31, 2023 results: revenue approximately $11.2 million to $11.3 million. Guidance initiated.
“Total revenue for the fourth quarter of 2023 is expected to be in the range of approximately $11.2 million to $11.3 million”
Nadim Yared departed as President and Chief Executive Officer at CVRx, Inc..
“its President and Chief Executive Officer, Nadim Yared, provided notice to the Company’s Board of Directors (the “Board”) of his plans to retire upon the completion of a deliberate succession process and the appointment of a successor.”
CVRx, Inc. incurred term loan of $15.0 million with Innovatus Life Sciences Fund I, LP.
“the Company borrowed $15.0 million under the second tranche of its term loan facility with Innovatus on Friday, December 15, 2023, the deadline for drawing the second tranche.”
CVRx, Inc. reported the third quarter of 2023 results: revenue $10.5 million, net income $9.0 million, EPS $0.43 per share.
“cardiovascular diseases, today announced its financial and operating results for the third quarter of 2023. Recent Highlights · Total revenue for the third quarter of 2023 was $10.5 million, an increase of 70% over the prior year quarter · U.S. Heart Failure (HF) revenue for the third quarter of 2023 was $9.4 million, an increase of 92% over the prior year quarter ·”
CVRx, Inc. reported the quarter ended June 30, 2023 results: revenue $9.5 million, net income $11.7 million, EPS $0.56 per share. Guidance raised.
“diseases, today announced its financial and operating results for the second quarter of 2023. Recent Highlights · Total revenue for the second quarter of 2023 was $ 9.5 million, an increase of 89 % over prior year quarter · U.S. Heart Failure (HF) revenue for the second quarter of 2023 was $ 8.3 million compared to $ 3.8 in the prior year quarter, an”
CVRx, Inc. shareholders approved Ratification of Grant Thornton LLP as independent registered public accounting firm at the 2023-06-05 meeting.
“Proposal 2. The stockholders ratified the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, by the votes set forth in the table below. For Against Abstain 18,785,665 641 9,526”
CVRx, Inc. shareholders approved Election of Directors at the 2023-06-05 meeting.
“Proposal 1. Election of Directors. The two nominees for Class II director were elected to serve until the 2026 annual meeting of stockholders and until their successors are duly elected and qualified, by the votes set forth in the table below. Nominee For Withheld Broker Non-Votes Kevin Hykes 12,368,856 617,120 5,809,856 Joseph Slattery 11,896,881 1,089,095 5,809,856”
CVRx, Inc. reported the first quarter of 2023 results: revenue $8.0 million, net income Net loss was $11.4 million, or $0.55 per share, EPS $0.55 per share. Guidance reaffirmed.
“year quarter ● Active implanting centers in the U.S. grew to 122, an increase of 118% over the first quarter of 2022 ● Worldwide revenue for the first quarter of 2023 was $8.0 million, an increase of 96% over prior year quarter “I am thrilled with our first quarter performance, which demonstrated solid execution on multiple fronts. We were able to share the”
CVRx, Inc. incurred term loan of $7.5 million remaining under the first tranche with Innovatus Life Sciences Fund I, LP.
“CVRx borrowed the $7.5 million remaining under the first tranche of its term loan facility with Innovatus”
CVRx, Inc. reported financial results for the fourth quarter and full year of 2022.
“On January 26, 2023, CVRx, Inc. issued a press release announcing its financial results for the quarter and year ended December 31, 2022. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.”
CVRx, Inc. reported the first quarter of 2023 results: revenue between $7.1 million and $7.5 million. Guidance initiated.
“Total revenue between $7.1 million and $7.5 million”
CVRx, Inc. reported the full year of 2023 results: revenue between $35.0 million and $38.0 million. Guidance initiated.
“Total revenue between $35.0 million and $38.0 million”
CVRx, Inc. reported the fiscal year ended December 31, 2022 results: revenue in the range of approximately $22.3 million to $22.4 million.
“Total revenue for full year 2022 is expected to be in the range of approximately $22.3 million to $22.4 million”
CVRx, Inc. reported the quarter ended December 31, 2022 results: revenue in the range of approximately $7.0 million to $7.1 million.
“Total revenue for the fourth quarter of 2022 is expected to be in the range of approximately $7.0 million to $7.1 million”
Kevin Hykes was appointed as Director at CVRx, Inc..
“On December 20, 2022, the Board of Directors (the “Board”) of CVRx, Inc. (the “Company”) approved an increase in the size of the Board from seven to eight members and appointed Kevin Hykes as a director effective December 21, 2022.”
CVRx, Inc. reported the three months ended September 30, 2022 results: revenue $6.2 million, net income $9.8 million, EPS $0.48 per share.
“Revenue was $6.2 million for the three months ended September 30, 2022, an increase of $2.8 million, or 82%, over the three months ended September 30, 2021. Revenue generated in the U.S. was $5.0 million for the three months ended September 30, 2022, an increase of $2.5 million, or 96%, over the three months ended September 30, 2021. Total HF revenue units in the U.S. totaled 167 and 84 for the three months ended September 30, 2022 and 2021, respectively. HF revenue in the U.S. totaled $4.9 million for the three months ended September 30, 2022, an increase of $2.4 million, or 99%, over the three months ended September 30, 2021. The increase was primarily driven by continued growth as a result of the expansion into new sales territories and new accounts, as well as increased physician and patient awareness of Barostim. As of September 30, 2022, we had a total of 91 active implanting centers as compared to 38 as of September 30, 2021. Active implanting centers are customers that have com”
CVRx, Inc. incurred credit facility of up to a total of $50.0 million with Innovatus Life Sciences Fund I, LP at a floating rate per annum equal to the sum of (a) the greater of (i) the prime r maturing January 31, 2028.
“On October 31, 2022, CVRx, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Loan Agreement”) with Innovatus Life Sciences Fund I, LP, as the collateral agent and a lender, and the other lenders from time to time party thereto, under which the Company may borrow, subject to the Company’s achievement of certain milestones, up to a total of $50.0 million in a series of three term loans. The term loans advanced pursuant to the Loan Agreement (collectively, the “Term Loans”) will bear interest at a floating rate per annum equal to the sum of (a) the greater of (i) the prime rate and (ii) 5.50% plus (b) 2.65%. The interest only period is five years followed by a three-month repayment period. The Term Loans mature on January 31, 2028.”
CVRx, Inc. entered into Loan Agreement with Innovatus Life Sciences Fund I, LP, as the collateral agent and a lender, and the other lenders from time to time party thereto valued at up to a total of $50.0 million (effective 2022-10-31).
“On October 31, 2022, CVRx, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Loan Agreement”) with Innovatus Life Sciences Fund I, LP, as the collateral agent and a lender, and the other lenders from time to time party thereto, under which the Company may borrow, subject to the Company’s achievement of certain milestones, up to a total of $50.0 million in a series of three term loans.”
Martha Shadan was appointed as Director at CVRx, Inc..
“the Board of Directors (the “Board”) of CVRx, Inc. (the “Company”) approved an increase in the size of the Board from seven to eight members and appointed Martha Shadan as a director effective July 12, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.